Semma Therapeutics Announces Pre-Clinical Proof-of-Concept in Two Lead Programs in Type 1 Diabetes
Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, announced the achievement of pre-clinical proof-of-concept based on…
Read More...
Read More...